{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:31:16Z","timestamp":1794947476175,"version":"4.9.1"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ferroptosis, an iron-dependent programmed cell death pathway driven by lipid peroxidation, offers a transformative approach to cancer therapy by exploiting unique cellular vulnerabilities. This comprehensive review elucidates the intricate molecular mechanisms of ferroptosis and their modulation by genetic mutations across diverse malignancies, including lung, hematological, liver, colorectal, breast, glioma, renal, pancreatic, thyroid, prostate, cervical, gastric, and melanoma. We delineate the critical functions of ferroptosis regulators, such as GPX4, system Xc\u207b, and iron metabolism proteins, in orchestrating the delicate balance between oxidative damage and antioxidant protection. The study further examines how oncogenic mutations in genes like EGFR, KRAS, TP53, KEAP1, and IDH1 reshape ferroptosis susceptibility or resistance through alterations in metabolic pathways, redox homeostasis, and tumor microenvironment interactions. By highlighting mutation-specific sensitivities, this work underscores the potential of ferroptosis-targeted strategies to surmount therapeutic resistance, synergize with conventional treatments like chemotherapy and immunotherapy, and drive precision oncology forward, paving the way for enhanced clinical outcomes across a broad spectrum of cancers.<\/jats:p>","DOI":"10.1038\/s41419-026-08796-w","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T03:38:35Z","timestamp":1778125115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Genetic mutations governing ferroptosis sensitivity and resistance: a precision approach to cancer therapy"],"prefix":"10.1038","volume":"17","author":[{"given":"Peyman","family":"Tabnak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1356-0540","authenticated-orcid":false,"given":"Mohammad","family":"Ebrahimnezhad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zanyar","family":"HajiEsmailPoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"8796_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2298-2","volume":"11","author":"J Li","year":"2020","unstructured":"Li J, Cao F, Yin H, Huang Z, Lin Z, Mao N, et al. Ferroptosis: past, present and future. Cell Death Dis. 2020;11:88.","journal-title":"Cell Death Dis"},{"key":"8796_CR2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41580-024-00703-5","volume":"25","author":"SJ Dixon","year":"2024","unstructured":"Dixon SJ, Olzmann JA. The cell biology of ferroptosis. Nat Rev Mol Cell Biol. 2024;25:424\u201342. https:\/\/doi.org\/10.1038\/s41580-024-00703-5.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8796_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.879317","volume":"13","author":"Z Nie","year":"2022","unstructured":"Nie Z, Chen M, Gao Y, Huang D, Cao H, Peng Y, et al. Ferroptosis and tumor drug resistance: current status and major challenges. Front Pharmacol. 2022;13:879317.","journal-title":"Front Pharmacol"},{"key":"8796_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y, et al. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduct Target Ther. 2024;9:55 https:\/\/doi.org\/10.1038\/s41392-024-01769-5.","journal-title":"Signal Transduct Target Ther"},{"key":"8796_CR5","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.molmed.2023.03.007","volume":"29","author":"D Ostroverkhova","year":"2023","unstructured":"Ostroverkhova D, Przytycka TM, Panchenko AR. Cancer driver mutations: predictions and reality. Trends Mol Med. 2023;29:554\u201366. https:\/\/doi.org\/10.1016\/j.molmed.2023.03.007.","journal-title":"Trends Mol Med"},{"key":"8796_CR6","doi-asserted-by":"crossref","unstructured":"Waarts MR, Stonestrom AJ, Park YC, Levine RL. Targeting mutations in cancer. J Clin Investig. 2022;132:e154943.","DOI":"10.1172\/JCI154943"},{"key":"8796_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100796","volume":"59","author":"R Nussinov","year":"2021","unstructured":"Nussinov R, Tsai C-J, Jang H. Anticancer drug resistance: an update and perspective. Drug Resist Updat. 2021;59:100796. https:\/\/doi.org\/10.1016\/j.drup.2021.100796.","journal-title":"Drug Resist Updat"},{"key":"8796_CR8","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22:381\u201396.","journal-title":"Nat Rev Cancer"},{"key":"8796_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/adbi.202100396","volume":"5","author":"Z Lin","year":"2021","unstructured":"Lin Z, Liu J, Kang R, Yang M, Tang D. Lipid metabolism in ferroptosis. Adv Biol. 2021;5:2100396.","journal-title":"Adv Biol"},{"key":"8796_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41420-021-00579-w","volume":"7","author":"Y Yu","year":"2021","unstructured":"Yu Y, Yan Y, Niu F, Wang Y, Chen X, Su G, et al. Ferroptosis: a cell death connecting oxidative stress, inflammation, and cardiovascular diseases. Cell Death Discov. 2021;7:193.","journal-title":"Cell Death Discov"},{"key":"8796_CR11","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1080\/15548627.2023.2218764","volume":"19","author":"Y Xie","year":"2023","unstructured":"Xie Y, Kang R, Klionsky DJ, Tang D. GPX4 in cell death, autophagy, and disease. Autophagy. 2023;19:2621\u201338.","journal-title":"Autophagy"},{"key":"8796_CR12","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","volume":"185","author":"BR Stockwell","year":"2022","unstructured":"Stockwell BR. Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022;185:2401\u201321.","journal-title":"Cell"},{"key":"8796_CR13","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s10637-021-01070-0","volume":"39","author":"M Liu","year":"2021","unstructured":"Liu M, Zhu W, Pei D. System Xc\u2212: a key regulatory target of ferroptosis in cancer. Investig New Drugs. 2021;39:1123\u201331.","journal-title":"Investig New Drugs"},{"key":"8796_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.910292","volume":"13","author":"F-J Li","year":"2022","unstructured":"Li F-J, Long H-Z, Zhou Z-W, Luo H-Y, Xu S-G, Gao L-C. System Xc\u2212\/GSH\/GPX4 axis: an important antioxidant system for the ferroptosis in drug-resistant solid tumor therapy. Front Pharmacol. 2022;13:910292.","journal-title":"Front Pharmacol"},{"key":"8796_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104907","volume":"214","author":"M Ebrahimnezhad","year":"2025","unstructured":"Ebrahimnezhad M, Valizadeh A, Yousefi B. Ferroptosis and immunotherapy: breaking barriers in cancer treatment resistance. Crit Rev Oncol Hematol. 2025;214:104907. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104907.","journal-title":"Crit Rev Oncol Hematol"},{"key":"8796_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-020-00428-9","volume":"6","author":"H Yan","year":"2021","unstructured":"Yan H, Zou T, Tuo Q, Xu S, Li H, Belaidi AA, et al. Ferroptosis: mechanisms and links with diseases. Signal Transduct Target Ther. 2021;6:49.","journal-title":"Signal Transduct Target Ther"},{"key":"8796_CR17","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41556-019-0305-6","volume":"21","author":"B Chu","year":"2019","unstructured":"Chu B, Kon N, Chen D, Li T, Liu T, Jiang L, et al. ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nat Cell Biol. 2019;21:579\u201391. https:\/\/doi.org\/10.1038\/s41556-019-0305-6.","journal-title":"Nat Cell Biol"},{"key":"8796_CR18","doi-asserted-by":"publisher","unstructured":"Rochette L, Dogon G, Rigal E, Zeller M, Cottin Y, Vergely C. Lipid peroxidation and iron metabolism: two corner stones in the homeostasis control of ferroptosis. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/ijms24010449.","DOI":"10.3390\/ijms24010449"},{"key":"8796_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.590226","volume":"8","author":"X Chen","year":"2020","unstructured":"Chen X, Yu C, Kang R, Tang D. Iron metabolism in ferroptosis. Front Cell Dev Biol. 2020;8:590226.","journal-title":"Front Cell Dev Biol"},{"key":"8796_CR20","doi-asserted-by":"crossref","unstructured":"Li W, Liang L, Liu S, Yi H, Zhou Y. FSP1: a key regulator of ferroptosis. Trends Mol Med. 2023;29:753\u2013764.","DOI":"10.1016\/j.molmed.2023.05.013"},{"key":"8796_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06045-y","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu Y, Lu S, Wu L, Yang L, Yang L, Wang J. The diversified role of mitochondria in ferroptosis in cancer. Cell Death Dis. 2023;14:519.","journal-title":"Cell Death Dis"},{"key":"8796_CR22","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.3390\/antiox12091739","volume":"12","author":"R Yan","year":"2023","unstructured":"Yan R, Lin B, Jin W, Tang L, Hu S, Cai R. NRF2, a superstar of ferroptosis. Antioxidants. 2023;12:1739.","journal-title":"Antioxidants"},{"key":"8796_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07224-1","volume":"15","author":"Y Chen","year":"2024","unstructured":"Chen Y, Jiang Z, Li X. New insights into crosstalk between Nrf2 pathway and ferroptosis in lung disease. Cell Death Dis. 2024;15:841. https:\/\/doi.org\/10.1038\/s41419-024-07224-1.","journal-title":"Cell Death Dis"},{"key":"8796_CR24","doi-asserted-by":"publisher","unstructured":"Verma SK, Pandey M, Khare R, Singh D. A review on non-small cell lung cancer. Vacunas. 2024;25:239\u201353. https:\/\/doi.org\/10.1016\/j.vacune.2024.05.013.","DOI":"10.1016\/j.vacune.2024.05.013"},{"key":"8796_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.adcanc.2022.100076","volume":"6","author":"A Kumar","year":"2022","unstructured":"Kumar A, Kumar A. Non-small-cell lung cancer-associated gene mutations and inhibitors. Adv Cancer Biol Metastasis. 2022;6:100076. https:\/\/doi.org\/10.1016\/j.adcanc.2022.100076.","journal-title":"Adv Cancer Biol Metastasis"},{"key":"8796_CR26","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.21037\/tlcr-22-235","volume":"11","author":"JP Casta\u00f1eda-Gonz\u00e1lez","year":"2022","unstructured":"Casta\u00f1eda-Gonz\u00e1lez JP, Chaves JJ, Parra-Medina R. Multiple mutations in the EGFR gene in lung cancer: a systematic review. Transl Lung Cancer Res. 2022;11:2148.","journal-title":"Transl Lung Cancer Res"},{"key":"8796_CR27","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3892\/ol.2024.14431","volume":"28","author":"C Wu","year":"2024","unstructured":"Wu C, Zhong R, Wei T, Jin Y, He C, Li H, et al. Mechanism of targeting the mTOR pathway to regulate ferroptosis in NSCLC with different EGFR mutations. Oncol Lett. 2024;28:298 https:\/\/doi.org\/10.3892\/ol.2024.14431.","journal-title":"Oncol Lett"},{"key":"8796_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-58499-5","volume":"14","author":"S Lv","year":"2024","unstructured":"Lv S, Pan Q, Lu W, Zhang W, Wang N, Huang L, et al. Tenovin 3 induces apoptosis and ferroptosis in EGFR 19del non small cell lung cancer cells. Sci Rep. 2024;14:7654. https:\/\/doi.org\/10.1038\/s41598-024-58499-5.","journal-title":"Sci Rep"},{"key":"8796_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41420-024-01892-w","volume":"10","author":"S Zhen","year":"2024","unstructured":"Zhen S, Jia Y, Zhao Y, Wang J, Zheng B, Liu T, et al. NEAT1_1 confers gefitinib resistance in lung adenocarcinoma through promoting AKR1C1-mediated ferroptosis defence. Cell Death Discov. 2024;10:131 https:\/\/doi.org\/10.1038\/s41420-024-01892-w.","journal-title":"Cell Death Discov"},{"key":"8796_CR30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.bbrc.2022.12.029","volume":"641","author":"H Konishi","year":"2023","unstructured":"Konishi H, Haga Y, Lin Y, Tsujino H, Higashisaka K, Tsutsumi Y. Osimertinib-tolerant lung cancer cells are susceptible to ferroptosis. Biochem Biophys Res Commun. 2023;641:116\u201322. https:\/\/doi.org\/10.1016\/j.bbrc.2022.12.029.","journal-title":"Biochem Biophys Res Commun"},{"key":"8796_CR31","doi-asserted-by":"crossref","unstructured":"Zhou Z, Zhao Y, Chen S, Cui G, Fu W, Li S, et al. Cisplatin promotes the efficacy of immune checkpoint inhibitor therapy by inducing ferroptosis and activating neutrophils. Front Pharmacol. 2022;13:870178.","DOI":"10.3389\/fphar.2022.870178"},{"key":"8796_CR32","doi-asserted-by":"crossref","unstructured":"Luo J, Ostrem J, Pellini B, Imbody D, Stern Y, Solanki HS, et al. Overcoming KRAS-mutant lung cancer. Am Soc Clin Oncol Educ Book. 2022;42:1\u201311.","DOI":"10.1200\/EDBK_360354"},{"key":"8796_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.923915","volume":"12","author":"C Andreani","year":"2022","unstructured":"Andreani C, Bartolacci C, Scaglioni PP. Ferroptosis: a specific vulnerability of RAS-driven cancers? Front Oncol. 2022;12:923915.","journal-title":"Front Oncol"},{"key":"8796_CR34","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1158\/1541-7786.MCR-22-0085","volume":"20","author":"NT Vu","year":"2022","unstructured":"Vu NT, Kim M, Stephenson DJ, MacKnight HP, Chalfant CE. Ceramide kinase inhibition drives ferroptosis and sensitivity to cisplatin in mutant KRAS lung cancer by dysregulating VDAC-mediated mitochondria function. Mol Cancer Res. 2022;20:1429\u201342.","journal-title":"Mol Cancer Res"},{"key":"8796_CR35","doi-asserted-by":"crossref","unstructured":"Chen L, Ning J, Linghu L, Tang J, Liu N, Long Y, et al. USP13 facilitates a ferroptosis-to-autophagy switch by activation of the NFE2L2\/NRF2-SQSTM1\/p62-KEAP1 axis dependent on the KRAS signaling pathway. Autophagy. 2024;21:1\u201318.","DOI":"10.1080\/15548627.2024.2410619"},{"key":"8796_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-3-030-62026-4_4","volume":"1301","author":"N Santana-Codina","year":"2021","unstructured":"Santana-Codina N, Gikandi A, Mancias JD. The role of NCOA4-mediated ferritinophagy in ferroptosis. Adv Exp Med Biol. 2021;1301:41\u201357. https:\/\/doi.org\/10.1007\/978-3-030-62026-4_4.","journal-title":"Adv Exp Med Biol"},{"key":"8796_CR37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41413-024-00350-8","volume":"12","author":"K Li","year":"2024","unstructured":"Li K, Yang B, Du Y, Ding Y, Shen S, Sun Z, et al. The HOXC10\/NOD1\/ERK axis drives osteolytic bone metastasis of pan-KRAS-mutant lung cancer. Bone Res. 2024;12:47. https:\/\/doi.org\/10.1038\/s41413-024-00350-8.","journal-title":"Bone Res"},{"key":"8796_CR38","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/pin.13403","volume":"74","author":"L Chen","year":"2024","unstructured":"Chen L, Sun R, Fang K. Erianin inhibits tumor growth by promoting ferroptosis and inhibiting invasion in hepatocellular carcinoma through the JAK2\/STAT3\/SLC7A11 pathway. Pathol Int. 2024;74:119\u201328. https:\/\/doi.org\/10.1111\/pin.13403.","journal-title":"Pathol Int"},{"key":"8796_CR39","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6093216","volume":"2022","author":"X-H Nie","year":"2022","unstructured":"Nie X-H, Qiu S, Xing Y, Xu J, Lu B, Zhao S-F, et al. Paeoniflorin regulates NEDD4L\/STAT3 pathway to induce ferroptosis in human glioma cells. J Oncol. 2022;2022:6093216. https:\/\/doi.org\/10.1155\/2022\/6093216.","journal-title":"J Oncol"},{"key":"8796_CR40","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jtho.2022.03.011","volume":"17","author":"S Scalera","year":"2022","unstructured":"Scalera S, Mazzotta M, Cortile C, Krasniqi E, De Maria R, Cappuzzo F, et al. KEAP1-mutant NSCLC: the catastrophic failure of a cell-protecting hub. J Thorac Oncol. 2022;17:751\u20137.","journal-title":"J Thorac Oncol"},{"key":"8796_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103305","volume":"75","author":"M S\u00e1nchez-Ortega","year":"2024","unstructured":"S\u00e1nchez-Ortega M, Garrido A, Cirauqui C, Sanz-Gonzalez L, Hern\u00e1ndez MC, Gonz\u00e1lez-Garc\u00eda A, et al. A potential therapeutic strategy based on acute oxidative stress induction for wild-type NRF2\/KEAP1 lung squamous cell carcinoma. Redox Biol. 2024;75:103305. https:\/\/doi.org\/10.1016\/j.redox.2024.103305.","journal-title":"Redox Biol"},{"key":"8796_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29905-1","volume":"13","author":"P Koppula","year":"2022","unstructured":"Koppula P, Lei G, Zhang Y, Yan Y, Mao C, Kondiparthi L, et al. A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers. Nat Commun. 2022;13:2206. https:\/\/doi.org\/10.1038\/s41467-022-29905-1.","journal-title":"Nat Commun"},{"key":"8796_CR43","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.18632\/oncotarget.28301","volume":"13","author":"N Emmanuel","year":"2022","unstructured":"Emmanuel N, Li H, Chen J, Zhang Y. FSP1, a novel KEAP1\/NRF2 target gene regulating ferroptosis and radioresistance in lung cancers. Oncotarget. 2022;13:1136.","journal-title":"Oncotarget"},{"key":"8796_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101160","volume":"77","author":"Z Yuan","year":"2024","unstructured":"Yuan Z, Wang X, Qin B, Hu R, Miao R, Zhou Y, et al. Targeting NQO1 induces ferroptosis and triggers anti-tumor immunity in immunotherapy-resistant KEAP1-deficient cancers. Drug Resist Updat. 2024;77:101160. https:\/\/doi.org\/10.1016\/j.drup.2024.101160.","journal-title":"Drug Resist Updat"},{"key":"8796_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108444","volume":"33","author":"CA Wohlhieter","year":"2020","unstructured":"Wohlhieter CA, Richards AL, Uddin F, Hulton CH, Quintanal-Villalonga \u00c0, Martin A, et al. Concurrent mutations in STK11 and KEAP1 promote ferroptosis protection and SCD1 dependence in lung cancer. Cell Rep. 2020;33:108444. https:\/\/doi.org\/10.1016\/j.celrep.2020.108444.","journal-title":"Cell Rep"},{"key":"8796_CR46","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s10616-024-00632-3","volume":"76","author":"Y Song","year":"2024","unstructured":"Song Y, Zhou D, Zhang P, Zhu N, Guo R, Wang T, et al. Heparanase accelerates the angiogenesis and inhibits the ferroptosis of p53-mutant non-small cell cancers in VEGF-dependent manner. Cytotechnology. 2024;76:503\u201317. https:\/\/doi.org\/10.1007\/s10616-024-00632-3.","journal-title":"Cytotechnology"},{"key":"8796_CR47","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.ajpath.2023.05.003","volume":"193","author":"M Peng","year":"2023","unstructured":"Peng M, Hu Q, Wu Z, Wang B, Wang C, Yu F. Mutation of TP53 confers ferroptosis resistance in lung cancer through the FOXM1\/MEF2C axis. Am J Pathol. 2023;193:1587\u2013602. https:\/\/doi.org\/10.1016\/j.ajpath.2023.05.003.","journal-title":"Am J Pathol"},{"key":"8796_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s13062-025-00613-2","volume":"20","author":"R Ma","year":"2025","unstructured":"Ma R, Yang D, Wang P, Zhang Z, Zhang X, Song J, et al. Oncogenic RIT1 mutations confer ferroptosis vulnerability in lung adenocarcinoma. Biol Direct. 2025;20:19. https:\/\/doi.org\/10.1186\/s13062-025-00613-2.","journal-title":"Biol Direct"},{"key":"8796_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07274-5","volume":"15","author":"Z Yuan","year":"2024","unstructured":"Yuan Z, Han X, Xiao M, Zhu T, Xu Y, Tang Q, et al. Overexpression of ELF3 in the PTEN-deficient lung epithelium promotes lung cancer development by inhibiting ferroptosis. Cell Death Dis. 2024;15:897. https:\/\/doi.org\/10.1038\/s41419-024-07274-5.","journal-title":"Cell Death Dis"},{"key":"8796_CR50","first-page":"1019","volume":"4","author":"R Zeng","year":"2021","unstructured":"Zeng R, Luo L, Sun X, Bao Z, Du W, Dai R, et al. EGFR\/BRAF\/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAFV600E mutation: a case report and review of literature. Cancer Drug Resist. 2021;4:1019.","journal-title":"Cancer Drug Resist"},{"key":"8796_CR51","doi-asserted-by":"publisher","unstructured":"Nokin M-J, Darbo E, Richard E, San Jos\u00e9 S, de Hita S, Prouzet-Mauleon V, et al. In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma. Cell Rep Med. 2024;5. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101663.","DOI":"10.1016\/j.xcrm.2024.101663"},{"key":"8796_CR52","doi-asserted-by":"publisher","DOI":"10.1515\/med-2023-0845","volume":"19","author":"Q Zou","year":"2024","unstructured":"Zou Q, Tang B, Chen X, Zhang C, Huang Y. STK11 (LKB1) mutation suppresses ferroptosis in lung adenocarcinoma by facilitating monounsaturated fatty acid synthesis. Open Med. 2024;19:20230845.","journal-title":"Open Med"},{"key":"8796_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103419","volume":"78","author":"K Wang","year":"2024","unstructured":"Wang K, Zhang X, Fan Y, Zhou L, Duan Y, Li S, et al. Reactivation of MAPK-SOX2 pathway confers ferroptosis sensitivity in KRASG12C inhibitor resistant tumors. Redox Biol. 2024;78:103419. https:\/\/doi.org\/10.1016\/j.redox.2024.103419.","journal-title":"Redox Biol"},{"key":"8796_CR54","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ccell.2024.03.011","volume":"42","author":"G Lei","year":"2024","unstructured":"Lei G, Zhuang L, Gan B. The roles of ferroptosis in cancer: tumor suppression, tumor microenvironment, and therapeutic interventions. Cancer Cell. 2024;42:513\u201334. https:\/\/doi.org\/10.1016\/j.ccell.2024.03.011.","journal-title":"Cancer Cell"},{"key":"8796_CR55","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.1158\/0008-5472.CAN-21-0567","volume":"81","author":"X Wang","year":"2021","unstructured":"Wang X, Chen Y, Wang X, Tian H, Wang Y, Jin J, et al. Stem cell factor SOX2 confers ferroptosis resistance in lung cancer via upregulation of SLC7A11. Cancer Res. 2021;81:5217\u201329.","journal-title":"Cancer Res"},{"key":"8796_CR56","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41556-024-01377-z","volume":"26","author":"PK Morgan","year":"2024","unstructured":"Morgan PK, Pernes G, Huynh K, Giles C, Paul S, Smith AAT, et al. A lipid atlas of human and mouse immune cells provides insights into ferroptosis susceptibility. Nat Cell Biol. 2024;26:645\u201359. https:\/\/doi.org\/10.1038\/s41556-024-01377-z.","journal-title":"Nat Cell Biol"},{"key":"8796_CR57","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41392-024-02088-5","volume":"10","author":"F Alves","year":"2025","unstructured":"Alves F, Lane D, Nguyen TPM, Bush AI, Ayton S. In defence of ferroptosis. Signal Transduct Target Ther. 2025;10:2 https:\/\/doi.org\/10.1038\/s41392-024-02088-5.","journal-title":"Signal Transduct Target Ther"},{"key":"8796_CR58","doi-asserted-by":"publisher","first-page":"a005975","DOI":"10.1101\/mcs.a005975","volume":"7","author":"E Lalonde","year":"2021","unstructured":"Lalonde E, Rentas S, Wertheim G, Cao K, Surrey LF, Lin F, et al. Clinical impact of genomic characterization of 15 patients with acute megakaryoblastic leukemia\u2013related malignancies. Mol Case Stud. 2021;7:a005975.","journal-title":"Mol Case Stud"},{"key":"8796_CR59","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/s43018-020-00115-2","volume":"1","author":"AM Savino","year":"2020","unstructured":"Savino AM, Fernandes SI, Olivares O, Zemlyansky A, Cousins A, Markert EK, et al. Metabolic adaptation of acute lymphoblastic leukemia to the central nervous system microenvironment depends on stearoyl-CoA desaturase. Nat Cancer. 2020;1:998\u20131009.","journal-title":"Nat Cancer"},{"key":"8796_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellin.2023.100091","volume":"2","author":"J Snyder","year":"2023","unstructured":"Snyder J, Wu Z. Origins of nervous tissue susceptibility to ferroptosis. Cell Insight. 2023;2:100091. https:\/\/doi.org\/10.1016\/j.cellin.2023.100091.","journal-title":"Cell Insight"},{"key":"8796_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59531-6","volume":"16","author":"A Garcia-Gimenez","year":"2025","unstructured":"Garcia-Gimenez A, Ditcham JE, Azazi DMA, Giotopoulos G, Asby R, Meduri E, et al. CREBBP inactivation sensitizes B cell acute lymphoblastic leukemia to ferroptotic cell death upon BCL2 inhibition. Nat Commun. 2025;16:4274.","journal-title":"Nat Commun"},{"key":"8796_CR62","doi-asserted-by":"crossref","unstructured":"Bai Y, Luo Y, Yuan Y, Li X, Jin J, Ping R, et al. Ferroptosis: a novel therapeutic warrior in the battle against leukemia. Apoptosis. 2025;30:1776\u20131795.","DOI":"10.1007\/s10495-025-02130-z"},{"key":"8796_CR63","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40164-020-00161-7","volume":"9","author":"J Yu","year":"2020","unstructured":"Yu J, Li Y, Zhang D, Wan D, Jiang Z. Clinical implications of recurrent gene mutations in acute myeloid leukemia. Exp Hematol Oncol. 2020;9:4 https:\/\/doi.org\/10.1186\/s40164-020-00161-7.","journal-title":"Exp Hematol Oncol"},{"key":"8796_CR64","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1158\/2159-8290.CD-22-0411","volume":"13","author":"M Sabatier","year":"2023","unstructured":"Sabatier M, Birsen R, Lauture L, Mouche S, Angelino P, Dehairs J, et al. C\/EBP\u03b1 confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress\u2013induced ferroptosis in FLT3-mutant leukemia. Cancer Discov. 2023;13:1720\u201347.","journal-title":"Cancer Discov"},{"key":"8796_CR65","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1182\/blood.2024024072","volume":"144","author":"N Hassan","year":"2024","unstructured":"Hassan N, Yi H, Malik B, Gaspard-Boulinc L, Samaraweera SE, Casolari DA, et al. Loss of the stress sensor GADD45A promotes stem cell activity and ferroptosis resistance in LGR4\/HOXA9-dependent AML. Blood. 2024;144:84\u201398.","journal-title":"Blood"},{"key":"8796_CR66","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.21873\/anticanres.16895","volume":"44","author":"H Kumada","year":"2024","unstructured":"Kumada H, Itoh M, Tohda S. Effect of ferroptosis inducers and inhibitors on cell proliferation in acute leukemia. Anticancer Res. 2024;44:1003\u201310.","journal-title":"Anticancer Res"},{"key":"8796_CR67","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1038\/s41375-022-01634-w","volume":"36","author":"Y Hong","year":"2022","unstructured":"Hong Y, Ren T, Wang X, Liu X, Fei Y, Meng S, et al. APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations. Leukemia. 2022;36:2269\u201380. https:\/\/doi.org\/10.1038\/s41375-022-01634-w.","journal-title":"Leukemia"},{"key":"8796_CR68","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1038\/s41375-022-01573-6","volume":"36","author":"B Pardieu","year":"2022","unstructured":"Pardieu B, Pasanisi J, Ling F, Dal Bello R, Penneroux J, Su A, et al. Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia. Leukemia. 2022;36:1585\u201395. https:\/\/doi.org\/10.1038\/s41375-022-01573-6.","journal-title":"Leukemia"},{"key":"8796_CR69","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.7150\/ijms.117603","volume":"22","author":"H Yu","year":"2025","unstructured":"Yu H, Wu X, Liu Y, Xin C, Zhou Y, Ding X. Single-gene mutations in hepatocellular carcinoma: applications and challenges in precision medicine. Int J Med Sci. 2025;22:3268.","journal-title":"Int J Med Sci"},{"key":"8796_CR70","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3350\/cmh.2015.21.3.220","volume":"21","author":"J-S Lee","year":"2015","unstructured":"Lee J-S. The mutational landscape of hepatocellular carcinoma. Clin Mol Hepatol. 2015;21:220.","journal-title":"Clin Mol Hepatol"},{"key":"8796_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51860-2","volume":"15","author":"W Zhao","year":"2024","unstructured":"Zhao W, Wang X, Han L, Zhang C, Wang C, Kong D, et al. SLC13A3 is a major effector downstream of activated \u03b2-catenin in liver cancer pathogenesis. Nat Commun. 2024;15:7522. https:\/\/doi.org\/10.1038\/s41467-024-51860-2.","journal-title":"Nat Commun"},{"key":"8796_CR72","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.7150\/ijbs.105446","volume":"21","author":"Z Ding","year":"2025","unstructured":"Ding Z, Li Z, Sun K, Liu Y, Fang Z, Sun S, et al. Mitochondrial regulation of ferroptosis in cancer cells. Int J Biol Sci. 2025;21:2179.","journal-title":"Int J Biol Sci"},{"key":"8796_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38753-6","volume":"14","author":"M Zhan","year":"2023","unstructured":"Zhan M, Ding Y, Huang S, Liu Y, Xiao J, Yu H, et al. Lysyl oxidase-like 3 restrains mitochondrial ferroptosis to promote liver cancer chemoresistance by stabilizing dihydroorotate dehydrogenase. Nat Commun. 2023;14:3123. https:\/\/doi.org\/10.1038\/s41467-023-38753-6.","journal-title":"Nat Commun"},{"key":"8796_CR74","doi-asserted-by":"publisher","first-page":"669","DOI":"10.7150\/jca.61622","volume":"13","author":"X Zheng","year":"2022","unstructured":"Zheng X, Liu B, Liu X, Li P, Zhang P, Ye F, et al. PERK regulates the sensitivity of hepatocellular carcinoma cells to high-LET carbon ions via either apoptosis or ferroptosis. J Cancer. 2022;13:669.","journal-title":"J Cancer"},{"key":"8796_CR75","doi-asserted-by":"publisher","first-page":"5476","DOI":"10.7150\/ijbs.111419","volume":"21","author":"B Quan","year":"2025","unstructured":"Quan B, Yao F, Liu W, Tang B, Li M, Lu S, et al. Increased CAPG inhibits ferroptosis to drive tumor proliferation and sorafenib resistance in hepatocellular carcinoma via the WDR74-p53-SLC7A11 pathway. Int J Biol Sci. 2025;21:5476\u201395. https:\/\/doi.org\/10.7150\/ijbs.111419.","journal-title":"Int J Biol Sci"},{"key":"8796_CR76","doi-asserted-by":"publisher","first-page":"88","DOI":"10.7150\/jca.65574","volume":"13","author":"Y-C Yan","year":"2022","unstructured":"Yan Y-C, Meng G-X, Ding Z-N, Liu Y-F, Chen Z-Q, Yan L-J, et al. Somatic mutation and expression of BAP1 in hepatocellular carcinoma: an indicator for ferroptosis and immune checkpoint inhibitor therapies. J Cancer. 2022;13:88.","journal-title":"J Cancer"},{"key":"8796_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2020.109633","volume":"72","author":"Y Shang","year":"2020","unstructured":"Shang Y, Luo M, Yao F, Wang S, Yuan Z, Yang Y. Ceruloplasmin suppresses ferroptosis by regulating iron homeostasis in hepatocellular carcinoma cells. Cell Signal. 2020;72:109633. https:\/\/doi.org\/10.1016\/j.cellsig.2020.109633.","journal-title":"Cell Signal"},{"key":"8796_CR78","doi-asserted-by":"publisher","unstructured":"Wang Q, Shen X, Chen G, Du J. Drug resistance in colorectal cancer: from mechanism to clinic. Cancers. 2022;14. https:\/\/doi.org\/10.3390\/cancers14122928.","DOI":"10.3390\/cancers14122928"},{"key":"8796_CR79","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1002\/1878-0261.12999","volume":"15","author":"P Kandasamy","year":"2021","unstructured":"Kandasamy P, Zlobec I, Nydegger DT, Pujol-Gim\u00e9nez J, Bhardwaj R, Shirasawa S, et al. Oncogenic KRAS mutations enhance amino acid uptake by colorectal cancer cells via the Hippo signaling effector YAP1. Mol Oncol. 2021;15:2782\u2013800. https:\/\/doi.org\/10.1002\/1878-0261.12999.","journal-title":"Mol Oncol"},{"key":"8796_CR80","doi-asserted-by":"publisher","unstructured":"Nguyen NT, Sennoune SR, Dharmalingam-Nandagopal G, Sivaprakasam S, Bhutia YD, Ganapathy V. Impact of oncogenic changes in p53 and KRAS on macropinocytosis and ferroptosis in colon cancer cells and anticancer efficacy of niclosamide with differential effects on these two processes. Cells 2024;13. https:\/\/doi.org\/10.3390\/cells13110951.","DOI":"10.3390\/cells13110951"},{"key":"8796_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102235","volume":"52","author":"J Zou","year":"2025","unstructured":"Zou J, Shi X, Wu Z, Zuo S, Tang X, Zhou H, et al. MRTX1133 attenuates KRASG12D mutated-colorectal cancer progression through activating ferroptosis activity via METTL14\/LINC02159\/FOXC2 axis. Transl Oncol. 2025;52:102235. https:\/\/doi.org\/10.1016\/j.tranon.2024.102235.","journal-title":"Transl Oncol"},{"key":"8796_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06848-7","volume":"15","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Lou S, Lu J, Zheng F, Tang Y, Zhang E, et al. Selective PI3K\u03b4 inhibitor TYM-3-98 suppresses AKT\/mTOR\/SREBP1-mediated lipogenesis and promotes ferroptosis in KRAS-mutant colorectal cancer. Cell Death Dis. 2024;15:474. https:\/\/doi.org\/10.1038\/s41419-024-06848-7.","journal-title":"Cell Death Dis"},{"key":"8796_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07227-y","volume":"15","author":"J Liu","year":"2024","unstructured":"Liu J, Wei X, Xie Y, Yan Y, Xue S, Wang X, et al. MDM4 inhibits ferroptosis in p53 mutant colon cancer via regulating TRIM21\/GPX4 expression. Cell Death Dis. 2024;15:825. https:\/\/doi.org\/10.1038\/s41419-024-07227-y.","journal-title":"Cell Death Dis"},{"key":"8796_CR84","doi-asserted-by":"publisher","unstructured":"Lei S, Chen C, Han F, Deng J, Huang D, Qian L, et al. AMER1 deficiency promotes the distant metastasis of colorectal cancer by inhibiting SLC7A11- and FTL-mediated ferroptosis. Cell Rep. 2023;42. https:\/\/doi.org\/10.1016\/j.celrep.2023.113110.","DOI":"10.1016\/j.celrep.2023.113110"},{"key":"8796_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2023.113697","volume":"430","author":"F Huang","year":"2023","unstructured":"Huang F, Huang Z, Wei Q, Liu G, Pu J. E3 ubiquitin ligase HECTD3 is a tumor suppressor and mediates the polyubiquitination of SLC7A11 to promote ferroptosis in colon cancer. Exp Cell Res. 2023;430:113697. https:\/\/doi.org\/10.1016\/j.yexcr.2023.113697.","journal-title":"Exp Cell Res"},{"key":"8796_CR86","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41413-024-00398-6","volume":"13","author":"Q Ru","year":"2025","unstructured":"Ru Q, Li Y, Zhang X, Chen L, Wu Y, Min J, et al. Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects. Bone Res. 2025;13:27 https:\/\/doi.org\/10.1038\/s41413-024-00398-6.","journal-title":"Bone Res"},{"key":"8796_CR87","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202104836","volume":"9","author":"Y Li","year":"2022","unstructured":"Li Y, Li J, Li Z, Wei M, Zhao H, Miyagishi M, et al. Homeostasis imbalance of YY2 and YY1 promotes tumor growth by manipulating ferroptosis. Adv Sci. 2022;9:2104836. https:\/\/doi.org\/10.1002\/advs.202104836.","journal-title":"Adv Sci"},{"key":"8796_CR88","doi-asserted-by":"publisher","unstructured":"Alalhareth IS, Alyami SM, Alshareef AH, Ajeibi AO, Al Munjem MF, Elfifi AA, et al. Cellular epigenetic targets and epidrugs in breast cancer therapy: mechanisms, challenges, and future perspectives. Pharmaceuticals. 2025;18. https:\/\/doi.org\/10.3390\/ph18020207.","DOI":"10.3390\/ph18020207"},{"key":"8796_CR89","doi-asserted-by":"crossref","unstructured":"Daniyal A, Santoso I, Gunawan NHP, Barliana MI, Abdulah R. Genetic influences in breast cancer drug resistance. Breast Cancer Targets Ther. 2021;13:59\u201385.","DOI":"10.2147\/BCTT.S284453"},{"key":"8796_CR90","doi-asserted-by":"publisher","unstructured":"Kong Y, Akatsuka S, Motooka Y, Zheng H, Cheng Z, Shiraki Y, et al. BRCA1 haploinsufficiency promotes chromosomal amplification under Fenton reaction-based carcinogenesis through ferroptosis-resistance. Redox Biol. 2022;54. https:\/\/doi.org\/10.1016\/j.redox.2022.102356 LK - http:\/\/rug.on.worldcat.org\/atoztitles\/link\/?sid=EMBASE&issn=22132317&id=doi:10.1016%2Fj.redox.2022.102356&atitle=BRCA1+haploinsufficiency+promotes+chromosomal+amplification+under+Fenton+reaction-based+carcinogenesis+through+ferroptosis-resistance&stitle=Redox+Biol.&title=Redox+Biology&volume=54&issue=&spage=&epage=&aulast=Kong&aufirst=Yingyi&auinit=Y.&aufull=Kong+Y.&coden=&isbn=&pages=-&date=2022&auinit1=Y&auinitm=.","DOI":"10.1016\/j.redox.2022.102356"},{"key":"8796_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103350","volume":"76","author":"X Xie","year":"2024","unstructured":"Xie X, Chen C, Wang C, Guo Y, Sun B, Tian J, et al. Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitors. Redox Biol. 2024;76:103350. https:\/\/doi.org\/10.1016\/j.redox.2024.103350.","journal-title":"Redox Biol"},{"key":"8796_CR92","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk1835","volume":"10","author":"D Dibra","year":"2024","unstructured":"Dibra D, Xiong S, Moyer SM, El-Naggar AK, Qi Y, Su X, et al. Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo. Sci Adv. 2024;10:eadk1835.","journal-title":"Sci Adv"},{"key":"8796_CR93","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.freeradbiomed.2021.09.013","volume":"176","author":"O Karmi","year":"2021","unstructured":"Karmi O, Sohn Y-S, Zandalinas SI, Rowland L, King SD, Nechushtai R, et al. Disrupting CISD2 function in cancer cells primarily impacts mitochondrial labile iron levels and triggers TXNIP expression. Free Radic Biol Med. 2021;176:92\u2013104. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2021.09.013.","journal-title":"Free Radic Biol Med"},{"key":"8796_CR94","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s41416-020-0814-x","volume":"122","author":"S Han","year":"2020","unstructured":"Han S, Liu Y, Cai SJ, Qian M, Ding J, Larion M, et al. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer. 2020;122:1580\u20139. https:\/\/doi.org\/10.1038\/s41416-020-0814-x.","journal-title":"Br J Cancer"},{"key":"8796_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1984-4","volume":"10","author":"T-X Wang","year":"2019","unstructured":"Wang T-X, Liang J-Y, Zhang C, Xiong Y, Guan K-L, Yuan H-X. The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis. Cell Death Dis. 2019;10:755. https:\/\/doi.org\/10.1038\/s41419-019-1984-4.","journal-title":"Cell Death Dis"},{"key":"8796_CR96","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1158\/1078-0432.CCR-22-3179","volume":"29","author":"Y Liu","year":"2023","unstructured":"Liu Y, Chou F-J, Lang F, Zhang M, Song H, Zhang W, et al. Protein kinase B (PKB\/AKT) protects IDH-mutated glioma from ferroptosis via Nrf2. Clin Cancer Res. 2023;29:1305\u201316.","journal-title":"Clin Cancer Res"},{"key":"8796_CR97","doi-asserted-by":"crossref","unstructured":"Lai K, Chen Z, Lin S, Ye K, Yuan Y, Li G, et al. The IDH1-R132H mutation aggravates cisplatin-induced acute kidney injury by promoting ferroptosis through disrupting NDUFA1 and FSP1 interaction. Cell Death Differ. 2024;32:1\u201314.","DOI":"10.1038\/s41418-024-01381-8"},{"key":"8796_CR98","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13578-022-00764-z","volume":"12","author":"F Yuan","year":"2022","unstructured":"Yuan F, Sun Q, Zhang S, Ye L, Xu Y, Deng G, et al. The dual role of p62 in ferroptosis of glioblastoma according to p53 status. Cell Biosci. 2022;12:20.","journal-title":"Cell Biosci"},{"key":"8796_CR99","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.urolonc.2018.10.027","volume":"38","author":"C D\u2019Avella","year":"2020","unstructured":"D\u2019Avella C, Abbosh P, Pal SK, Geynisman DM. Mutations in renal cell carcinoma. Urol Oncol Semin Orig Investig. 2020;38:763\u201373. https:\/\/doi.org\/10.1016\/j.urolonc.2018.10.027.","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"8796_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114098","volume":"148","author":"Z Yan","year":"2025","unstructured":"Yan Z, Li Y, Wang M, Xu K, Liu Y, Wang L, et al. O-GlcNAcylation of DJ-1 suppresses ferroptosis in renal cell carcinoma by affecting the transsulfuration pathway. Int Immunopharmacol. 2025;148:114098. https:\/\/doi.org\/10.1016\/j.intimp.2025.114098.","journal-title":"Int Immunopharmacol"},{"key":"8796_CR101","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/7736638","volume":"2023","author":"CY Kuo","year":"2023","unstructured":"Kuo CY, Hsieh PC, Chiu V, Lan CC, Lu KC. The von hippel-lindau tumor suppressor gene mutations modulate lipocalin-2 expression in ferroptotic-inflammatory pathways. Oxid Med Cell Longev. 2023;2023:7736638. https:\/\/doi.org\/10.1155\/2023\/7736638.","journal-title":"Oxid Med Cell Longev"},{"key":"8796_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09277-9","volume":"10","author":"Y Zou","year":"2019","unstructured":"Zou Y, Palte MJ, Deik AA, Li H, Eaton JK, Wang W, et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat Commun. 2019;10:1617. https:\/\/doi.org\/10.1038\/s41467-019-09277-9.","journal-title":"Nat Commun"},{"key":"8796_CR103","doi-asserted-by":"publisher","first-page":"8674","DOI":"10.7150\/thno.60233","volume":"11","author":"Q Zheng","year":"2021","unstructured":"Zheng Q, Li P, Zhou X, Qiang Y, Fan J, Lin Y, et al. Deficiency of the X-inactivation escaping gene KDM5C in clear cell renal cell carcinoma promotes tumorigenicity by reprogramming glycogen metabolism and inhibiting ferroptosis. Theranostics. 2021;11:8674\u201391. https:\/\/doi.org\/10.7150\/thno.60233.","journal-title":"Theranostics"},{"key":"8796_CR104","doi-asserted-by":"crossref","unstructured":"Wang K, Zhang Z, Wang M, Cao X, Qi J, Wang D, et al. Role of GRP78 inhibiting artesunate-induced ferroptosis in KRAS mutant pancreatic cancer cells. Drug Des Devel Ther. 2019;13:2135\u201344.","DOI":"10.2147\/DDDT.S199459"},{"key":"8796_CR105","doi-asserted-by":"publisher","unstructured":"Marcus R, Ferri-Borgogno S, Hosein A, Foo WC, Ghosh B, Zhao J, et al. Oncogenic KRAS requires complete loss of BAP1 function for development of murine intrahepatic cholangiocarcinoma. Cancers. 2021;13. https:\/\/doi.org\/10.3390\/cancers13225709.","DOI":"10.3390\/cancers13225709"},{"key":"8796_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00268-022-06738-z","volume":"47","author":"KR Sekhar","year":"2023","unstructured":"Sekhar KR, Cyr S, Baregamian N. Ferroptosis inducers in thyroid cancer. World J Surg. 2023;47:1 https:\/\/doi.org\/10.1007\/s00268-022-06738-z.","journal-title":"World J Surg"},{"key":"8796_CR107","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1002\/tox.24304","volume":"39","author":"J Xiong","year":"2024","unstructured":"Xiong J, Chen P, He L, Chai X, Zhang Y, Sun S. Functional mechanism of hypoxia-like conditions mediating resistance to ferroptosis in cervical cancer cells by regulating KDM4A SUMOylation and the SLC7A11\/GPX4 pathway. Environ Toxicol. 2024;39:4207\u201320. https:\/\/doi.org\/10.1002\/tox.24304.","journal-title":"Environ Toxicol"},{"key":"8796_CR108","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1158\/0008-5472.CAN-22-1159","volume":"83","author":"CK Wang","year":"2023","unstructured":"Wang CK, Chen TJ, Tan GYT, Chang FP, Sridharan S, Yu C-HA, et al. MEX3A mediates p53 degradation to suppress ferroptosis and facilitate ovarian cancer tumorigenesis. Cancer Res. 2023;83:251\u201363. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-1159.","journal-title":"Cancer Res"},{"key":"8796_CR109","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1158\/1541-7786.MCR-23-0930","volume":"22","author":"PDB Tiburcio","year":"2024","unstructured":"Tiburcio PDB, Desai K, Kim J, Zhou Q, Guo L, Xiao X, et al. DROSHA regulates mesenchymal gene expression in Wilms tumor. Mol Cancer Res. 2024;22:711\u201320.","journal-title":"Mol Cancer Res"},{"key":"8796_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115329","volume":"206","author":"G Li","year":"2022","unstructured":"Li G, Lin S, Yu Z, Wu X, Liu J, Tu G, et al. A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer. Biochem Pharmacol. 2022;206:115329. https:\/\/doi.org\/10.1016\/j.bcp.2022.115329.","journal-title":"Biochem Pharmacol"},{"key":"8796_CR111","doi-asserted-by":"publisher","unstructured":"Varga D, Hajdin\u00e1k P, Makk-Merczel K, Szarka A. The possible connection of two dual function processes: the relationship of ferroptosis and the JNK pathway. Int J Mol Sci. 2022;23. https:\/\/doi.org\/10.3390\/ijms231911004.","DOI":"10.3390\/ijms231911004"},{"key":"8796_CR112","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1158\/1535-7163.MCT-21-0728","volume":"21","author":"J Li","year":"2022","unstructured":"Li J, Lama R, Galster SL, Inigo JR, Wu J, Chandra D, et al. Small-molecule MMRi62 induces ferroptosis and inhibits metastasis in pancreatic cancer via degradation of ferritin heavy chain and mutant p53. Mol Cancer Ther. 2022;21:535\u201345. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0728.","journal-title":"Mol Cancer Ther"},{"key":"8796_CR113","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/s41416-021-01566-9","volume":"125","author":"T Ishida","year":"2021","unstructured":"Ishida T, Takahashi T, Kurokawa Y, Nishida T, Hirota S, Serada S, et al. Targeted therapy for drug-tolerant persister cells after imatinib treatment for gastrointestinal stromal tumours. Br J Cancer. 2021;125:1511\u201322. https:\/\/doi.org\/10.1038\/s41416-021-01566-9.","journal-title":"Br J Cancer"},{"key":"8796_CR114","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bbrc.2021.06.051","volume":"567","author":"J Ni","year":"2021","unstructured":"Ni J, Chen K, Zhang J, Zhang X. Inhibition of GPX4 or mTOR overcomes resistance to Lapatinib via promoting ferroptosis in NSCLC cells. Biochem Biophys Res Commun. 2021;567:154\u201360. https:\/\/doi.org\/10.1016\/j.bbrc.2021.06.051.","journal-title":"Biochem Biophys Res Commun"},{"key":"8796_CR115","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3324\/haematol.2020.259531","volume":"107","author":"R Birsen","year":"2022","unstructured":"Birsen R, Larrue C, Decroocq J, Johnson N, Guiraud N, Gotanegre M, et al. APR-246 induces early cell death by ferroptosis in acute myeloid leukemia. Haematologica. 2022;107:403\u201316. https:\/\/doi.org\/10.3324\/haematol.2020.259531.","journal-title":"Haematologica"},{"key":"8796_CR116","doi-asserted-by":"publisher","first-page":"116832","DOI":"10.1016\/j.biopha.2024.116832","volume":"176","author":"W Liao","year":"2024","unstructured":"Liao W, Zhang R, Chen G, Zhu X, Wu W, Chen Z, et al. Berberine synergises with ferroptosis inducer sensitizing NSCLC to ferroptosis in p53-dependent SLC7A11-GPX4 pathway. Biomed Pharmacother. 2024;176:116832 https:\/\/doi.org\/10.1016\/j.biopha.2024.116832.","journal-title":"Biomed Pharmacother"},{"key":"8796_CR117","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.freeradbiomed.2023.05.008","volume":"204","author":"Q Miao","year":"2023","unstructured":"Miao Q, Deng W, Lyu W, Sun Z, Fan S, Qi M, et al. Erianin inhibits the growth and metastasis through autophagy-dependent ferroptosis in KRASG13D colorectal cancer. Free Radic Biol Med. 2023;204:301\u201312.","journal-title":"Free Radic Biol Med"},{"key":"8796_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106739","volume":"191","author":"C Xu","year":"2023","unstructured":"Xu C, Jiang Z-B, Shao L, Zhao Z-M, Fan X-X, Sui X, et al. \u03b2-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer. Pharmacol Res. 2023;191:106739.","journal-title":"Pharmacol Res"},{"key":"8796_CR119","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.7150\/thno.44705","volume":"10","author":"P Chen","year":"2020","unstructured":"Chen P, Li X, Zhang R, Liu S, Xiang Y, Zhang M, et al. Combinative treatment of \u03b2-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation. Theranostics. 2020;10:5107.","journal-title":"Theranostics"},{"key":"8796_CR120","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1080\/19768354.2018.1512521","volume":"22","author":"S Park","year":"2018","unstructured":"Park S, Oh J, Kim M, Jin E-J. Bromelain effectively suppresses Kras-mutant colorectal cancer by stimulating ferroptosis. Animal Cells Syst. 2018;22:334\u201340.","journal-title":"Animal Cells Syst"},{"key":"8796_CR121","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3892\/ijo.2022.5447","volume":"61","author":"X Liu","year":"2022","unstructured":"Liu X, Hai Y, Dong J, Xu L, Hou W, Su J, et al. Realgar\u2011induced KRAS mutation lung cancer cell death via KRAS\/Raf\/MAPK mediates ferroptosis. Int J Oncol. 2022;61:157 https:\/\/doi.org\/10.3892\/ijo.2022.5447.","journal-title":"Int J Oncol"},{"key":"8796_CR122","doi-asserted-by":"crossref","unstructured":"Wei-Ya YAN, Jian CAI, Jiang-Nan W, Yong-Sheng G, Xue-Bing D. Co-treatment of betulin and gefitinib is effective against EGFR wild-type\/KRAS-mutant non-small cell lung cancer by inducing ferroptosis. Neoplasma. 2022;69:648\u201356.","DOI":"10.4149\/neo_2022_211103N1568"},{"key":"8796_CR123","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.jcis.2024.01.153","volume":"662","author":"L Wang","year":"2024","unstructured":"Wang L, Wang T, Zhuo Y, Xu S, Liu H, Jiang X, et al. Cascade Co8FeS8@ Co1-xS nano-enzymes trigger efficiently apoptosis-ferroptosis combination tumor therapy. J Colloid Interface Sci. 2024;662:962\u201375.","journal-title":"J Colloid Interface Sci"},{"key":"8796_CR124","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41418-022-01096-8","volume":"30","author":"F M\u00fcller","year":"2023","unstructured":"M\u00fcller F, Lim JKM, Bebber CM, Seidel E, Tishina S, Dahlhaus A, et al. Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation. Cell Death Differ. 2023;30:442\u201356.","journal-title":"Cell Death Differ"},{"key":"8796_CR125","doi-asserted-by":"publisher","unstructured":"Cardona CJ, Hermann ER, Kouplen KN, Hartson SD, Montgomery MR. Differences in antioxidant and lipid handling protein expression influence how cells expressing distinct mutant TP53 subtypes maintain iron homeostasis. Cells. 2022;11. https:\/\/doi.org\/10.3390\/cells11132064.","DOI":"10.3390\/cells11132064"},{"key":"8796_CR126","doi-asserted-by":"publisher","unstructured":"Thompson LR, Oliveira TG, Hermann ER, Chowanadisai W, Clarke SL, Montgomery MR. Distinct TP53 mutation types exhibit increased sensitivity to ferroptosis independently of changes in iron regulatory protein activity. Int J Mol Sci. 2020;21. https:\/\/doi.org\/10.3390\/ijms21186751.","DOI":"10.3390\/ijms21186751"},{"key":"8796_CR127","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1038\/s41388-021-01790-w","volume":"40","author":"G Lei","year":"2021","unstructured":"Lei G, Zhang Y, Hong T, Zhang X, Liu X, Mao C, et al. Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity. Oncogene. 2021;40:3533\u201347. https:\/\/doi.org\/10.1038\/s41388-021-01790-w.","journal-title":"Oncogene"},{"key":"8796_CR128","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1101\/gad.340919.120","volume":"35","author":"N Kon","year":"2021","unstructured":"Kon N, Ou Y, Wang S-J, Li H, Rustgi AK, Gu W. mTOR inhibition acts as an unexpected checkpoint in p53-mediated tumor suppression. Genes Dev. 2021;35:59\u201364.","journal-title":"Genes Dev"},{"key":"8796_CR129","doi-asserted-by":"crossref","unstructured":"Cahuzac KM, Lubin A, Bosch K, Stokes N, Shoenfeld SM, Zhou R, et al. AKT activation because of PTEN loss upregulates xCT via GSK3\u03b2\/NRF2, leading to inhibition of ferroptosis in PTEN-mutant tumor cells. Cell Rep. 2023;42:112536.","DOI":"10.1016\/j.celrep.2023.112536"},{"key":"8796_CR130","doi-asserted-by":"publisher","first-page":"31189","DOI":"10.1073\/pnas.2017152117","volume":"117","author":"J Yi","year":"2020","unstructured":"Yi J, Zhu J, Wu J, Thompson CB, Jiang X. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proc Natl Acad Sci USA. 2020;117:31189\u201397.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8796_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05592-8","volume":"14","author":"V Bhatt","year":"2023","unstructured":"Bhatt V, Lan T, Wang W, Kong J, Lopes EC, Wang J, et al. Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors. Cell Death Dis. 2023;14:61. https:\/\/doi.org\/10.1038\/s41419-023-05592-8.","journal-title":"Cell Death Dis"},{"key":"8796_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101171","volume":"78","author":"Z He","year":"2025","unstructured":"He Z, Zheng D, Li F, Chen L, Wu C, Zeng Z, et al. TMOD3 accelerated resistance to immunotherapy in KRAS-mutated pancreatic cancer through promoting autophagy-dependent degradation of ASCL4. Drug Resist Updat. 2025;78:101171. https:\/\/doi.org\/10.1016\/j.drup.2024.101171.","journal-title":"Drug Resist Updat"},{"key":"8796_CR133","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg3049","volume":"15","author":"J Li","year":"2025","unstructured":"Li J, Liu J, Zhou Z, Wu R, Chen X, Yu C, et al. Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer. Sci Transl Med. 2025;15:eadg3049. https:\/\/doi.org\/10.1126\/scitranslmed.adg3049.","journal-title":"Sci Transl Med"},{"key":"8796_CR134","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.4036","volume":"42","author":"DS Rathnayake","year":"2024","unstructured":"Rathnayake DS, Dlamini S, Elkalawozgy K, Tillekeratne LMV, Taylor WR. Mutant p53 reactivators protect breast cancer cells from ferroptosis. Cell Biochem Funct. 2024;42:e4036. https:\/\/doi.org\/10.1002\/cbf.4036.","journal-title":"Cell Biochem Funct"},{"key":"8796_CR135","doi-asserted-by":"publisher","first-page":"128","DOI":"10.7150\/ijbs.99423","volume":"21","author":"X Chen","year":"2025","unstructured":"Chen X, Chen X, Xie W, Ge H, He H, Zhang A, et al. BRAF-activated ARSI suppressed EREG-mediated ferroptosis to promote BRAFV600E (mutant) papillary thyroid carcinoma progression and sorafenib resistance. Int J Biol Sci. 2025;21:128\u201342. https:\/\/doi.org\/10.7150\/ijbs.99423.","journal-title":"Int J Biol Sci"},{"key":"8796_CR136","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06360-4","volume":"14","author":"L Dunsche","year":"2023","unstructured":"Dunsche L, Ivanisenko N, Riemann S, Schindler S, Beissert S, Angeli C, et al. A cytosolic mutp53(E285K) variant confers chemoresistance of malignant melanoma. Cell Death Dis. 2023;14:831. https:\/\/doi.org\/10.1038\/s41419-023-06360-4.","journal-title":"Cell Death Dis"},{"key":"8796_CR137","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/s41388-023-02599-5","volume":"42","author":"AM Minikes","year":"2023","unstructured":"Minikes AM, Song Y, Feng Y, Yoon C, Yoon SS, Jiang X. E-cadherin is a biomarker for ferroptosis sensitivity in diffuse gastric cancer. Oncogene. 2023;42:848\u201357. https:\/\/doi.org\/10.1038\/s41388-023-02599-5.","journal-title":"Oncogene"},{"key":"8796_CR138","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1093\/neuonc\/noab114","volume":"23","author":"Z Bao","year":"2021","unstructured":"Bao Z, Hua L, Ye Y, Wang D, Li C, Xie Q, et al. MEF2C silencing downregulates NF2 and E-cadherin and enhances Erastin-induced ferroptosis in meningioma. Neuro Oncol. 2021;23:2014\u201327. https:\/\/doi.org\/10.1093\/neuonc\/noab114.","journal-title":"Neuro Oncol"},{"key":"8796_CR139","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.21037\/tcr.2020.01.62","volume":"9","author":"F Tang","year":"2020","unstructured":"Tang F, Li S, Liu D, Chen J, Han C. Sorafenib sensitizes melanoma cells to vemurafenib through ferroptosis. Transl Cancer Res. 2020;9:1584.","journal-title":"Transl Cancer Res"},{"key":"8796_CR140","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/ddr.22059","volume":"84","author":"D Pamarthy","year":"2023","unstructured":"Pamarthy D, Behera SK, Swain S, Yadav S, Suresh S, Jain N, et al. Diaryl ether derivative inhibits GPX4 expression levels to induce ferroptosis in thyroid cancer cells. Drug Dev Res. 2023;84:861\u201387. https:\/\/doi.org\/10.1002\/ddr.22059.","journal-title":"Drug Dev Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08796-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08796-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08796-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:02:24Z","timestamp":1782781344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08796-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":140,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8796"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08796-w","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"During the preparation of this work, the authors used ChatGPT by OpenAI to improve paper readability. After using this tool\/service, the authors reviewed and edited the content as needed and took full responsibility for the publication\u2019s content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}}],"article-number":"606"}}